336 related articles for article (PubMed ID: 26248830)
1. N-of-1 trials in oncology.
Collette L; Tombal B
Lancet Oncol; 2015 Aug; 16(8):885-6. PubMed ID: 26248830
[No Abstract] [Full Text] [Related]
2. [Scientific evidence-based cancer treatments].
Expósito Hernández J; Aguado de Hoyos E; Rodríguez del Castillo M
Med Clin (Barc); 1999 Apr; 112(12):465-9. PubMed ID: 10320962
[No Abstract] [Full Text] [Related]
3. The role of nonrandomized trials in the evaluation of oncology drugs.
Simon R; Blumenthal GM; Rothenberg ML; Sommer J; Roberts SA; Armstrong DK; LaVange LM; Pazdur R
Clin Pharmacol Ther; 2015 May; 97(5):502-7. PubMed ID: 25676488
[TBL] [Abstract][Full Text] [Related]
4. Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?
A'Hern RP
J Clin Oncol; 2016 Oct; 34(28):3474-6. PubMed ID: 27507871
[No Abstract] [Full Text] [Related]
5. Comparison of anticipated and actual control group outcomes in randomised trials in paediatric oncology provides evidence that historically controlled studies are biased in favour of the novel treatment.
Moroz V; Wilson JS; Kearns P; Wheatley K
Trials; 2014 Dec; 15():481. PubMed ID: 25490968
[TBL] [Abstract][Full Text] [Related]
6. Unbelievable Folly of Clinical Trials in Heart Failure: The Inconvenient Truth About How Investigators and Guidelines Weigh Evidence.
Packer M
Circ Heart Fail; 2016 Apr; 9(4):e002837. PubMed ID: 27009552
[No Abstract] [Full Text] [Related]
7. Cancer concepts and principles: primer for the interventional oncologist-part I.
Hickey R; Vouche M; Sze DY; Hohlastos E; Collins J; Schirmang T; Memon K; Ryu RK; Sato K; Chen R; Gupta R; Resnick S; Carr J; Chrisman HB; Nemcek AA; Vogelzang RL; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2013 Aug; 24(8):1157-64. PubMed ID: 23809510
[TBL] [Abstract][Full Text] [Related]
8. Pathology is a necessary and informative tool in oncology clinical trials.
Nagtegaal ID; West NP; van Krieken JH; Quirke P
J Pathol; 2014 Jan; 232(2):185-9. PubMed ID: 24037805
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial design in oncology: assessment of outcomes.
Gebski V
Lancet Oncol; 2004 Dec; 5(12):761-3. PubMed ID: 15600005
[No Abstract] [Full Text] [Related]
10. Design considerations in clinical trials with cure rate survival data: A case study in oncology.
Sun S; Liu G; Lyu T; Xue F; Yeh TM; Rao S
Pharm Stat; 2018 Mar; 17(2):94-104. PubMed ID: 29159922
[TBL] [Abstract][Full Text] [Related]
11. Beyond effect size: consideration of the minimum effect size of interest in anesthesia trials.
Gibbs NM; Weightman WM
Anesth Analg; 2012 Feb; 114(2):471-5. PubMed ID: 22266696
[No Abstract] [Full Text] [Related]
12. Primer: measuring the effects of treatment in clinical trials.
Ward MM
Nat Clin Pract Rheumatol; 2007 May; 3(5):291-7. PubMed ID: 17471248
[TBL] [Abstract][Full Text] [Related]
13. Oncology trial design: More accurately and efficiently advancing the field.
Hohl RJ
Clin Pharmacol Ther; 2015 May; 97(5):430-2. PubMed ID: 25684240
[No Abstract] [Full Text] [Related]
14. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.
Bedard PL; Krzyzanowska MK; Pintilie M; Tannock IF
J Clin Oncol; 2007 Aug; 25(23):3482-7. PubMed ID: 17687153
[TBL] [Abstract][Full Text] [Related]
15. [Health related quality of life and endpoints in oncology].
Bonnetain F
Cancer Radiother; 2010 Oct; 14(6-7):515-8. PubMed ID: 20674446
[TBL] [Abstract][Full Text] [Related]
16. How good is "evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs?
Naci H; Ioannidis JP
Annu Rev Pharmacol Toxicol; 2015; 55():169-89. PubMed ID: 25149917
[TBL] [Abstract][Full Text] [Related]
17. Data handling in cancer clinical trials-how we can minimize potential biases.
Sakamoto J; Teramukai S
Jpn J Clin Oncol; 2002 Jan; 32(1):1-2. PubMed ID: 11932354
[No Abstract] [Full Text] [Related]
18. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.
Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053
[No Abstract] [Full Text] [Related]
19. Continuous toxicity monitoring in phase II trials in oncology.
Ivanova A; Qaqish BF; Schell MJ
Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
[TBL] [Abstract][Full Text] [Related]
20. Impact of COVID-19 Outbreak through Telemedicine Implementation on Data Reporting During Oncology Clinical Trials.
Bouleftour W; Daguenet E; Tinquaut F; Magne N
Cancer Invest; 2021 Jan; 39(1):15-20. PubMed ID: 33258396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
